1P-LSD vs LSD: What the Research Shows

Is 1P-LSD really different from LSD? This article summarises what laboratory and human studies show, the risks the two share, dangerous combinations, warning signs and how the law treats them.

Scientist looking through a microscope in a research laboratory, representing studies comparing 1P-LSD and LSD

Educational content. This article does not provide dosing, sourcing or buying information. It explains health risks so readers can make safer decisions and recognise when someone needs help.

1P-LSD was marketed for years as a “legal alternative” to LSD. That framing suggested it was a different, perhaps milder, substance. Scientific research tells a different story. This article looks at what studies have found when comparing 1P-LSD and LSD, what remains unknown, and what that means for health risks.

What are LSD and 1P-LSD?

LSD (lysergic acid diethylamide) is a classic hallucinogen first made in 1938. It has been studied extensively, including in modern clinical trials, and has been internationally controlled since 1971.

1P-LSD (1-propionyl-LSD) is a lysergamide: a modified version of LSD with an extra chemical group attached. It appeared on the online market around 2015, largely because it was not named in drug laws at the time. For a general introduction, see our earlier article What Is 1P-LSD?

What the research shows

1P-LSD behaves as a “prodrug” for LSD

The key finding is that 1P-LSD appears to act largely as a prodrug: once in the body, the extra chemical group is removed and the compound is converted into LSD itself.

  • Laboratory and animal studies published from 2016 onwards found that 1P-LSD is converted to LSD in blood serum and in animals, and that it produces LSD-like effects in standard animal tests.
  • A small controlled human study published in 2020 detected LSD in the blood of volunteers who had been given 1P-LSD, supporting the prodrug explanation.
1P-LSDenters the bodyConvertedpropionyl group removedLSDacts on 5-HT2A receptorsStudies suggest the effects of 1P-LSD come mainly from the LSD it turns into
Research indicates 1P-LSD works mainly as a prodrug: the body converts it into LSD.

Effects are reported as very similar

Self-reports and the limited research available describe effects that closely resemble LSD: changes in perception, thinking and mood, altered sense of time and strong emotional experiences. Some people report subtle differences in onset or feel, but there is little controlled evidence on this, and expectation plays a large role in how psychedelic experiences are described.

What we still don’t know

  • There are very few human studies, and they involved small numbers of healthy volunteers.
  • Long-term effects of repeated 1P-LSD use have not been studied directly.
  • Products sold as 1P-LSD are unregulated, so their purity and content cannot be assumed.

What this means for risk

Because 1P-LSD appears to turn into LSD, the sensible assumption is that it carries the same risks as LSD – plus the extra uncertainty that comes with an unregulated product. The “legal alternative” label never meant “safer alternative”.

Reported side effects (both substances)

  • Anxiety, panic and confusion
  • Raised heart rate and blood pressure, dilated pupils
  • Nausea and restlessness
  • Difficulty sleeping
  • Lingering visual changes in some people

Main health risks

  • Difficult experiences (“bad trips”) – intense fear or paranoia can lead to risky behaviour, accidents and injuries.
  • Mental health – hallucinogens can trigger or worsen psychosis in people with a personal or family history of psychotic illness or bipolar disorder.
  • HPPD – a small number of people experience persistent visual disturbances after use.
  • Mislabelled products – blotters sold as LSD or 1P-LSD have sometimes contained NBOMe compounds, which are far more dangerous. See our article on 2C-x, NBOMe and DOx risks.

Our wider guide to LSD analogues and their health risks covers related compounds such as 1cP-LSD and AL-LAD.

Dangerous combinations

These are listed as risks, not as guidance:

  • Lithium – combinations with hallucinogens have been linked to seizures.
  • Tramadol – raises seizure risk and serotonin-related risks.
  • Stimulants and other serotonergic drugs (MDMA, cathinones, some antidepressants) – greater strain on the heart and a risk of serotonin syndrome.
  • Cannabis – can make experiences more intense and anxiety-provoking.
  • Alcohol – impairs judgement and increases accident risk.

Emergency warning signs

  • Seizures
  • Very high body temperature, rigid muscles or severe confusion
  • Chest pain or a very fast heartbeat
  • Extreme panic, aggression or behaviour that puts the person in danger
  • Loss of consciousness

What to do

  • For physical warning signs, call 112 (EU), 999 (UK) or 911 (US).
  • Stay with the person, keep the environment calm, quiet and safe, and speak reassuringly.
  • If they are unconscious but breathing, place them in the recovery position.
  • Tell medical staff what you think was taken – it helps them treat the person.

Legal status

This is a general overview, not legal advice.

  • LSD is controlled under the UN 1971 Convention and is illegal in the EU, the UK and the US (Class A in the UK, Schedule I in the US).
  • 1P-LSD is not named in the UN conventions, but many countries now control it: in the UK it falls under the Psychoactive Substances Act 2016, in Germany under the NpSG, and in the US it may be treated as an LSD analogue under the Federal Analogue Act. The position in other countries has changed over time.

For a country-by-country explanation, see Is 1P-LSD Legal?

Getting help

  • Netherlands: Drugs Infolijn (Trimbos Institute); DIMS for anonymous drug-checking.
  • UK: FRANK – 0300 123 6600.
  • US: SAMHSA National Helpline – 1-800-662-4357.

Related reading

Frequently asked questions

Is 1P-LSD the same as LSD?

Chemically they are different molecules, but research indicates the body converts 1P-LSD into LSD, so its effects and risks should be assumed to be essentially the same.

Is 1P-LSD safer than LSD?

There is no evidence that it is. It shares LSD’s risks and adds the uncertainty of an unregulated product with little research behind it.

Can a blotter sold as 1P-LSD contain something else?

Yes. Testing services have found blotters containing other substances, including NBOMe compounds. Only laboratory testing can confirm what a blotter contains.

This article is for general information and is not medical advice. If you are worried about your own or someone else’s drug use, speak to a doctor or one of the services listed above.

Share on Twitter
✦ Written by
Research Chemicals Blog Editorial Team

The Research Chemicals Blog editorial team writes independent guides on laboratory chemicals, reagents and suppliers, and evidence-based drug-safety information drawn from public-health sources such as the EU Drugs Agency, WHO, NHS and NIDA. We never sell, recommend or link to sellers of psychoactive substances, and we never publish dosing or sourcing information.

ResearchChemicals.blog

© 2026 researchchemicals.blog · Independent guides for laboratory buyers. Not affiliated with any supplier named on this site.